Investigation of the clinical value of five tumor markers in cervical cancer

Objectives: To investigate the clinical value of the serum levels of cancer antigen 125 (CA125), carbohydrate antigen 19 9 (CA19 9), cytokeratin 19 fragments (CYFRA21 1), squamous cell carcinoma antigen (SCC) and carcinoembryonic antigen (CEA) in patients with cervical cancer. Methods: CA125, CA19 9 and CYFRA21 1 were measured by immunoradiometric assay, SCC and CEA were measured by enzyme linked immunosorbent assay. Twenty eight healthy females, 16 cervical intraepithelial neoplasia and 63 patients with cervical cancer were detected. Results: The levels of CYFRA21 1 and SCC in cervical cancer were significantly higher than that of healthy females and cervical intraepithelial neoplasia(P 0.05 ). The positive rate of CYFRA21 1, SCC and CEA in patients with cervical cancer increased with advance of the clinical stages (P 0.05 ). The positive rates of CYFRA21 1 and SCC were different with histological differentiation. The positive rate of CA125 and CA19 9 were found significantly higher among patients with adenocarcinoma than those with squamous cell carcinoma. The sensitivity and utility can be increased with combination of CYFRA21 1+SCC+CA19 9 in diagnosis of cervical cancer.Conclusions: These five tumor markers can be detected in patients with cervical cancer, there are specifically clinical application value of CYFRA21 1 and SCC for diagnosis and monitoring the progress of the disease.